From November 17 to 20, 2025, at the 54th MEDICA – International Medical Fair held in Düsseldorf, Germany, Biotest and its U.S. subsidiary ADVIN BIOTECH emerged as highly distinguishable representatives among exhibitors. With cutting-edge technologies, a comprehensive product portfolio, and a global layout, they fully demonstrated their innovative strength and development potential in the in vitro diagnostic (IVD) field.

 

Cutting-Edge Exploration, Comprehensive Coverage

At this year’s exhibition, Biotest and ADVIN BIOTECH presented a range of innovative achievements, with their flagship technology platform — FluidicNow™ microfluidic immunoassay technology — attracting considerable on-site attention. After a new round of continuous iteration and upgrading, both the detection range and sensitivity have been significantly enhanced. Equipped with high-sensitivity sensors, this technology can accurately identify trace biomarkers and support rapid simultaneous detection of multiple indicators. It is not only suitable for emergency and intensive care scenarios in large hospitals but also meets the needs of primary healthcare and mobile testing. Breaking application boundaries with "full-scenario adaptability," the technology perfectly embodies the R&D philosophy of "empowering medical accessibility through technology," winning unanimous praise from professional visitors at the exhibition.

Also making their debut were the OralTwist series of trace saliva drug testing products, SalivaTracer series of trace saliva drug testing products, DiagPal™ series of Lateral Flow Readers, new multi-item gastrointestinal tract testing reagents, and new Vitamin D rapid testing reagents. This diverse product portfolio, featuring the core advantages of "accuracy, convenience, and professionalism," covers various testing scenarios and meets the diversified needs of global users.

Focus on Self-Testing, Collaborate for Win-Win

At the exhibition, Biotest conducted multiple rounds of in-depth negotiations with global partners, laying a solid foundation for product line improvement and regional customized development. Building on its existing portfolio of 126 IVDR certifications, Biotest will prioritize the refined development of its self-test product line, with accelerated acquisition of additional IVDR certifications as a key driver. Tailoring products to European users’ usage habits, the company aims to achieve in-depth localized penetration in the European market. Taking Europe as a strategic pivot to expand globally, Biotest is constructing a market layout characterized by "local adaptation + global synergy."

      

Technology Translated into Action, Brand Built for Tomorrow

Taking MEDICA 2025 as a catalyst, Biotest will continue to deepen local cooperation and channel development. Committed to transforming advanced rapid testing technologies into convenient, reliable tools for personal health management, the company aims to achieve a leap from product export to brand value elevation, ushering in a new phase of its global strategy. Moving forward, relying on core technologies and global collaboration, Biotest will consistently launch diagnostic products that are more aligned with clinical needs and more competitive in the market. These efforts will provide accurate and reliable tool support for global healthcare systems, injecting strong momentum into the building of a global community of health for all.